Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability

Development of next-generation oncolytic viruses requires the design of vectors that are potently oncolytic, immunogenic in human tumors, and well tolerated in patients. Starting with a joint-region deleted herpes simplex virus 1 (HSV-1) to create large transgene capability, we retained a single cop...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, Edward M., Farkaly, Terry, Grzesik, Peter, Lee, Jennifer, Denslow, Agnieszka, Hewett, Jacqueline, Bryant, Jeffrey, Behara, Prajna, Goshert, Caitlin, Wambua, Daniel, De Almeida, Ana, Jacques, Judith, Deavall, Damian, Rottman, James B., Glorioso, Joseph C., Finer, Mitchell H., Haines, Brian B., Quéva, Christophe, Lerner, Lorena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479328/
https://www.ncbi.nlm.nih.gov/pubmed/32953982
http://dx.doi.org/10.1016/j.omto.2020.08.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479328/
https://www.ncbi.nlm.nih.gov/pubmed/32953982
http://dx.doi.org/10.1016/j.omto.2020.08.004

Ejemplares similares